Some investors might be at least a little more nervous about Vertex Pharmaceuticals (NASDAQ: VRTX) now than they were only a few days ago. Why? The big biopharmaceutical company provided its third-quarter update after the market close on Monday.

What are investors' specific concerns? How serious are those concerns? Here are four reasons some might worry about Vertex -- and how those reasons are easily debunked.

The obvious reason to worry after Vertex's Q3 update is that the company missed Wall Street's revenue estimate. There were quite a few articles published Monday evening and Tuesday highlighting this fact. But it's important to keep four things in mind.

Continue reading

Source Fool.com